- Thinly traded nano cap Hemispherx Biopharma (HEB -19.2%) slumps on more than double normal volume in response to its announcement of a private $5M equity placement with two institutional investors. The deal consists of common stock at $1.50, with each share being paired with one five-year warrant to purchase 3/4 of a share of common at $2.00.
- Net proceeds will fund technology transfer opportunities, expenses related to Ampligen manufacturing, working capital and general corporate purposes.
- Yesterday's close was $1.77.